



International Society for Cutaneous Lymphomas

## Cutaneous T Cell Lymphoma Symposium

Presiders: Joan Guitart MD, Larisa Geskin, MD, Sam Hwang, MD, PhD, and Gary Wood, MD

Friday, April 28, 2017

12:00pm-1:30pm

C123 & C124, Oregon Convention Center

12:00-12:10 ISCL Announcements

*8 minutes for presentation + 2 minutes for Q&A and change of speaker*

1. 12:10-12:20 **Cutaneous Lymphoma Foundation's Young Investigator's Award**
2. 12:20-12:30 **Anti-PD-L1 mAb reduces tumor growth in a mouse model of cutaneous T cell lymphoma.** Xuesong Wu, K Wang and S Hwang. *Abstract Final ID #273*
3. 12:30-12:40 **Epigenetically-enhanced PDT (ePDT) induces significantly higher levels of multiple extrinsic pathway apoptotic factors than conventional PDT, resulting in greater extrinsic and overall apoptosis of CTCL.** Gary Wood, K Salva and Y Kim. *Abstract Final ID #312*
4. 12:40-12:50 **SATB1 overexpression defines a subtype of cutaneous CD30+ lymphoproliferative disorders associated with Th17 cytokine profile.** Yang Wang, J Sun, S Yi, P Tu and M Kadin. *Abstract Final ID #115*
5. 12:50-1:00 **p38 $\gamma$  and its complementary pathway in cutaneous T cell lymphoma.** Xu Hannah Zhang, S Nam, J Wu, C Chen, Y Chen, C Querfeld, D Horne and S Rosen. *Abstract Final ID #309*
6. 1:00-1:10 **MicroRNA based classifiers in diagnosis and prognosis of cutaneous T cell lymphoma.** Bo Wang, X Shen and J Zheng. *Abstract Final ID #287*
7. 1:10-1:20 **Th2-dominant microenvironment by IL-25 in cutaneous T-cell lymphoma.** Chu-Tomomitsu Miyagaki, R Nakajima, T Oka, N Takahasi, M Hirakawa, H Suga, H Fujita, M Sugaya and S Sato. *Abstract Final ID #259*
8. 1:20-1:30 **Combination Bcl-2 and HDAC inhibition in the treatment of cutaneous T-cell lymphoma.** Benoit Cyrenne, J Lewis, J Weed, F Mirza, K Carlson and M Girardi. *Abstract Final ID #694*

*Visit [www.cutaneouslymphoma.org](http://www.cutaneouslymphoma.org) for more information about the ISCL and membership!*